NCT02271997

Brief Summary

Multicentre randomized controlled trial to evaluate the optimal treatment for patients who developed an iron deficiency after Roux-en-Y Gastric bypass.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Dec 2014

Typical duration for phase_4

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 22, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

December 4, 2014

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2017

Completed
Last Updated

January 18, 2019

Status Verified

January 1, 2019

Enrollment Period

2.5 years

First QC Date

October 20, 2014

Last Update Submit

January 16, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • normal value serum ferritin

    1 year after initiating therapy

    1 year

Secondary Outcomes (1)

  • patients preference for oral or intravenous therapy

    1 year

Study Arms (3)

Ferrous fumarate

ACTIVE COMPARATOR

40 patients receive ferrous fumarate 3 times a day 200mg

Drug: Ferrous fumarate

Ferrous gluconate

ACTIVE COMPARATOR

40 patients receive ferrous gluconate 2 times a day 695 mg

Drug: Ferrous gluconate

Iron(III)carboxymaltose

ACTIVE COMPARATOR

40 patients receive a single intravenous shot of ferinject

Drug: Iron(III)carboxymaltose

Interventions

treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured

Ferrous fumarate

treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured

Also known as: Losferron
Ferrous gluconate

treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured

Also known as: Ferinject
Iron(III)carboxymaltose

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • all women who underwent a Roux-en-Y gastric bypass and developed an iron deficiency postoperatively (ferritin\<20microgram/L)

You may not qualify if:

  • iron deficiency peroperative, blood transfusions during study period, iron containing nutritional supplements except the standard multivitamins after bariatric surgery, decreased renal failure, excessive blood loss due to menstruation, anemia not caused by iron deficiency, accumulation of iron, hypersensitivity for noe of the medicinal products, psychiatric illness, pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

OLVG West/ Sint Lucas Andreas Ziekenhuis

Amsterdam, North Holland, 1061 AE, Netherlands

Location

Rijnstate hospital

Arnhem, 6800WC, Netherlands

Location

Rose Kruis Ziekenhuis

Beverwijk, Netherlands

Location

Related Publications (1)

  • Schijns W, Boerboom A, de Bruyn Kops M, de Raaff C, van Wagensveld B, Berends FJ, Janssen IMC, van Laarhoven CJHM, de Boer H, Aarts EO. A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery. Clin Nutr. 2020 Dec;39(12):3779-3785. doi: 10.1016/j.clnu.2020.04.010. Epub 2020 Apr 21.

MeSH Terms

Conditions

Iron Deficiencies

Interventions

ferrous fumarateferrous gluconateferric carboxymaltose

Condition Hierarchy (Ancestors)

Iron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2014

First Posted

October 22, 2014

Study Start

December 4, 2014

Primary Completion

June 6, 2017

Study Completion

June 6, 2017

Last Updated

January 18, 2019

Record last verified: 2019-01

Locations